Bleep Sleep
Seed
Bleep Sleep develops FDA-cleared, headgear-free CPAP interfaces for sleep apnea therapy.
Founded
2015Bleep Sleep develops FDA-cleared, headgear-free CPAP interfaces for sleep apnea therapy.
Bleep Sleep sells two primary CPAP interfaces: DreamPorts, the original adhesive nasal interface, and Eclipse, a next-generation mask using MagSeal magnetic attachment technology. Both products eliminate traditional headgear and use disposable adhesive seals.
Products are FDA-cleared, manufactured in the United States, and available direct-to-consumer or through DME and insurance channels.
The U.S. obstructive sleep apnea therapy market remains dominated by ResMed, Philips, and Fisher & Paykel, but patient comfort and mask-adherence challenges sustain demand for alternative interfaces. Headgear-free designs address a documented pain point: leaks, skin irritation, and difficulty sleeping with bulky masks.
Bleep Sleep targets consumers and reimbursed channels as CPAP adoption grows among diagnosed apnea patients. Its adhesive-interface approach competes in a niche between minimalist nasal pillows and full-face masks, with room to expand if Medicare and insurer coverage broadens for novel mask categories.
Bleep Sleep differentiates its CPAP interfaces by eliminating traditional headgear entirely. DreamPorts and Eclipse use adhesive seals and magnetic attachment instead of mask straps, reducing facial pressure marks, leaks at the nose bridge, and claustrophobia common with conventional masks.
The company manufactures products in the United States, holds FDA clearance, and sells through direct-to-consumer, DME, Medicare, and private insurance channels—combining a novel form factor with established reimbursement pathways.